90685-59-9

Usage

Uses

Used in Pharmaceutical Industry:
6,7-Dihydro-5H-cyclopenta[b]pyridin-7-yl Acetate is used as a pharmaceutical intermediate for its potential role in the development of drugs. Its unique structure allows it to be a key component in the synthesis of various medicinal compounds, contributing to the creation of new therapeutic agents.
Used in Chemical Synthesis:
In the chemical synthesis industry, 6,7-Dihydro-5H-cyclopenta[b]pyridin-7-yl Acetate is utilized as a precursor in the production of other organic compounds. Its versatile structure makes it a valuable building block for synthesizing a range of chemical products, including specialty chemicals and advanced materials.

Upstream product

• 90685-58-8 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide 
• 108-24-7 acetic anhydride 
• 56946-65-7 2,4-dichloro-6,7-dihydro-5H-cyclopenta[b]pyridine 
• 533-37-9 2,3-cyclopentenopyridine 
• 64-19-7 acetic acid 

Downstream Products

• 270-91-7 5H-1-pyrindine 
• 270-92-8 7H-cyclopenta[b]pyridine 
• 253-69-0 [1,7]naphthyridine 
• 253-72-5 1,6-naphthyridine 
• 1333210-37-9 (1aR,6aS)-6,6a-dihydro-1aH-oxireno[4,5]cyclopenta[1,2-b]pyridine 
• 1333210-27-7 4-({(5R,6R)-6-[(3R)-3-aminopiperidin-1-yl]-6, 7-dihydro-5H-cyclopenta[b]pyridin-5-yl}oxy)-3-chlorobenzonitrile 
• 1333210-28-8 4-({(6R,7S)-6-[(3R)-3-aminopiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl}oxy)-3-chlorobenzonitrile 
• 1333210-38-0 (1aS,6aR) 2,6b-dihydro-1aH-oxireno[3,4]cyclopenta[1,2-b]pyridine 
• 1356401-48-3 C₂₅H₂₉ClN₄O₃ 
• 41598-71-4 7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridine 
• 31170-78-2 5H,6H,7H-cyclopenta[b]pyridin-7-one 
• 912277-45-3 (R)-5H,6H,7H-cyclopenta[b]pyridin-7-ol 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Cyclic gyrase and topoisomerase IV inhibitor

The invention belongs to the technical field of medicament, and particularly relates to a compound shown in formula (I) (please see the formula (I) in the description), and acceptable salt, ester or stereoisomer of the compound in pharmacy. R1, R2, a ring

Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues via chemical or enzymatic resolution of 1-pyrindan-7-ol

In this work, the enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers - rasagiline analogues - via chemical and/or enzymatic resolution of the racemic precursor 1-pyrindan-7-ol is described. (R)-Methoxyphenylacetic acid - (R)-MPAA - and (S)-methoxyphenylacetic acid - (S)-MPAA were used as chemical resolution agents, whereas Candida antarctica lipase B (CALB) was employed as kinetic resolution catalyst. The enzymatic resolution was successfully achieved by two different approaches: (1) transesterification of racemic 1-pyrindan-7-ol, which was found to selectively acylate the (R)-enantiomer with high efficiency; (2) hydrolysis of the racemic 7-(1-pyrindanyl)acetate, which was also highly selective to the (R)-enantiomer. The enzymatic hydrolysis was performed in a non-aqueous solvent using a lipase with significant absorbed water content. The configuration of the two enantiomers of 1-pyrindan-7-ol (and consequently of the 7-(1-pyrindanyl)propargyl ethers) were unequivocally determined by X-ray crystallography and/or specific optical rotation.

Organocatalysts with carbon-centered activity for CO2 reduction with boranes

We report two organocatalysts for CO2 hydroboration to methylborylethers, which upon hydrolysis can produce methanol. These organocatalysts feature carbon-centered reversible CO2 binding, broad borane scopes, and high catalytic activities.

Synthesis of New Propargylated 1-Pyrindane Derivatives as Rasagiline Analogues

Rasagiline is a compound with important neuroprotective activity applicable to the treatment of neurodegenerative diseases. This work describes an easy and straightforward methodology to the synthesis of new propargylated rasagiline analogues derived from commercially available 6,7-dihydro-5H-cyclopenta[b] pyridine. Georg Thieme Verlag Stuttgart - New York.

DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS

The instant invention relates to derivatives of formula (I) and their application in therapeutics.

Derivatives of aminoindanes, their preparation and their application in therapeutics

The instant invention relates to derivatives of formula (I) and their application in therapeutics.

Palladium-catalyzed acetoxylation of sp3 C-H bonds using molecular oxygen

Molecular oxygen as oxidant to promote palladium-catalyzed acetoxylation of sp3 C-H bonds to afford α-oxygenated products is reported.

FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF

The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

A New Approach to the Preparation of 1,6- and 1,7-Naphthyridines

Substituted 1,6- and 1,7-naphthyridines can be prepared by a simple route from readily available pyrindane; this method is more flexible and produces higher yields than previous routes.